UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.29 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 14.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 59,326 shares of the specialty pharmaceutical company’s stock after selling 9,984 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.18% of Collegium Pharmaceutical worth $2,292,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC boosted its stake in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,600 shares during the period. GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC raised its position in Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares in the last quarter. AXA S.A. acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth $209,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Collegium Pharmaceutical by 61.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company’s stock valued at $239,000 after purchasing an additional 2,352 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $30.09 on Friday. The company has a market cap of $970.40 million, a PE ratio of 12.97 and a beta of 0.80. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 52 week low of $28.75 and a 52 week high of $42.29. The business has a 50 day moving average price of $33.24 and a 200-day moving average price of $34.37.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on COLL shares. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright raised their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.